Biora Therapeutics, Inc.

BIORQ

US74319F4046

Biotechnology & Medical Research

Real-time OTC Markets Other stock markets 11:32:51 06/11/2025 pm IST			5-day change	1st Jan Change
0.000100 ^USD	-.--%		-.--%	-

30/12	Biora Therapeutics, Inc. Went Out of Business	CI
27/25/27	Motion For Case Conversion Approved for Biora Therapeutics, Inc.	CI

Biora Therapeutics, Inc.(OTCPK:BIOR) dropped from S&P TMI Index

Published on 12/13/2024

S&P Capital IQ

BIORA THERAPEUTICS, INC.

-.--%

S&P TMI

+0.96%

Biora Therapeutics, Inc.(OTCPK:BIOR) dropped from S&P TMI Index

Stocks mentioned in the article

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Price	Change	5d. change	Capi.
	BIORA THERAPEUTICS, INC.	0.000100USD	-.--%	-.--%	4
	S&P TMI	6,670.70PTS	+0.96%	-1.56%	-

Latest news about Biora Therapeutics, Inc.

30/12	Biora Therapeutics, Inc. Went Out of Business	CI
27/25/27	Motion For Case Conversion Approved for Biora Therapeutics, Inc.	CI
09/25/09	Motion for Case Conversion Filed by Biora Therapeutics, Inc.	CI
27/25/27	Motion for Asset Sale Approved for Biora Therapeutics, Inc.	CI
19/25/19	Final DIP Financing Approved for Biora Therapeutics, Inc.	CI
18/25/18	Notice For The Selection Of Successful Bidder And Auction Cancelled Filed by Biora Therapeutics, Inc.	CI
27/25/27	Bidding Procedure Approved for Biora Therapeutics, Inc.	CI
17/25/17	Stalking Horse Asset Purchase Agreement Filed by Biora Therapeutics, Inc.	CI
06/25/06	Motion for Asset Sale Filed by Biora Therapeutics, Inc.	CI
30/24/30	Biora Therapeutics Files for Chapter 11, Secures $10.25 Million Financing for Sale Process	MT
30/24/30	Interim DIP Financing Approved for Biora Therapeutics, Inc.	CI
27/24/27	Biora Therapeutics, Inc. Filed for Bankruptcy	CI
13/24/13	Biora Therapeutics, Inc.(OTCPK:BIOR) dropped from S&P TMI Index	CI
10/24/10	Top Midday Decliners	MT
10/24/10	Top Premarket Decliners	MT

Chart Biora Therapeutics, Inc.

Duration

Period

BIORQ: Dynamic Chart

Biora Therapeutics, Inc. is a biotechnology company, which is focused on creating smart pills designed for targeted drug delivery to the gastrointestinal (GI) tract, and systemic, needle-free delivery of biotherapeutics. The Companyâ€™s pipeline includes two therapeutic delivery platforms: NaviCap and BioJet. The NaviCap, targeted oral delivery platform, which is designed to improve outcomes for patients with inflammatory bowel disease through treatment at the site of disease in the gastrointestinal tract. The BioJet, systemic oral delivery platform, which is designed to replace injection for better management of chronic diseases through needle-free, oral delivery of large molecules. It has two demonstration drug-device combination programs for the BioJet platform, BT-200 (GLP-1 receptor agonist) and BT-002 (adalimumab variant). Its other two programs include BT-600 (NaviCap + tofacitinib) and BT-001 (NaviCap + variant of adalimumab) for the treatment of ulcerative colitis.

Employees

Sector

Biotechnology & Medical Research

More about the company